Study of the association between co-morbidities with COVID-19 and resulting morbidity and mortality: a hospital-based study in Uttar Pradesh, India
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20262270Keywords:
COVID-19, Co-morbidities, Mortality, RecoveryAbstract
Background: The pandemicity caused by SARS-CoV-2 virus led to increased number of morbidity and mortality worldwide. The clinical conditions, and the population infected were varied. For a new disease like this, it is very important to collectively measure all the co-morbidities being faced by the patients so that clinical case in future can be improved. The objective of this present study was to conduct a retrospective analysis of the patients infected with COVID-19 and study their clinical conditions and consequences.
Methods: The retrospective analysis of clinical conditions, comorbidities, complications etc. of COVID-19 infected patients (survived and not survived) was studied for the period 2020-2021.
Results: Varied type of infections were observed, such as anaemia, systemic sepsis, lower respiratory tract infections (LRTI), hypertension (HTN), type 2 diabetes mellitus (T2DM), and type 1 respiratory failure (T1RF). Some of these comorbidities were interconnected and can be considered to be the cause of poor prognostic results and fast clinical deterioration. Cardiopulmonary arrest, cardiorespiratory failure, acute respiratory distress syndrome (ARDS), pneumonia and complications due to COVID-19 were the main reasons of death found in the cohort studied.
Conclusions: The results highlight the significance of proactive management techniques for early identification of high-risk individuals, and integrated, multidisciplinary care approaches for patients with multiple morbidities.
References
Ebede SO, Orabueze IN, Nwafia IN, Emeribe SC, Okeke UC. Emergence of the SARS-CoV-2 XEC subvariant: public health concerns and preparedness in Nigeria. Dis Public Hlth. 2025;22(1):411.
World Health Organization. COVID-19, 2025. Available at: https://covid19.who.int/. Assessed June 20, 2025.
Girardin JL, Seixas A, Ramos Cejudo J, Osorio RS, Avirappattu G, Reid M, et al. Contribution of pulmonary diseases to COVID-19 mortality in a diverse urban community of New York. Chron Respir Dis. 2021;18:1479973120986806.
Thakur D, Gera T, Bhardwaj V, AlZubi AA, Ali F, Singh J. An enhanced diabetes prediction amidst COVID-19 using ensemble models. Front Public Health. 2023;11:1331517.
Cho DH, Choi J, Gwon JG. Metabolic syndrome and the risk of COVID-19 infection: A nationwide population-based case-control study. Nutr Metab Cardiovasc Dis. 2021;31(9):2596-604.
Nouchi A, Chastang J, Miyara M, Lejeune J, Soares A, Ibanez G, et al. Prevalence of hyposmia and hypogeusia in 390 COVID-19 hospitalized patients and outpatients: a cross-sectional study. Eur J Clin Microbiol Infect Dis. 2021;40(4):691-7.
Butowt R, von Bartheld CS. Anosmia in COVID-19: underlying mechanisms and assessment of an olfactory route to brain infection. Neuroscientist. 2021; 27(6):582-603.
Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11(1):16144.
Joshee S, Vatti N, Chang C. Long-term effects of COVID-19. In Mayo Clinic Proceed. 2022;97(3):579-99.
Adab P, Haroon S, O’Hara ME, Jordan RE. Comorbidities and covid-19. BMJ. 2022;377.
Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020;2(8):1069-76.
Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of sex, age, and comorbidities with mortality in COVID-19 patients: a systematic review and meta-analysis. Intervirol. 2021;64(1):36-47.
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-9.
Kabarriti R, Brodin NP, Maron MI, Guha C, Kalnicki S, Garg MK, et al. Association of race and ethnicity with comorbidities and survival among patients with COVID-19 at an Urban Medical Center in New York. JAMA Netw Open. 2020;3(9):e2019795.
Boaventura P, Macedo S, Ribeiro F, Jaconiano S, Soares P. Post-COVID-19 condition: where are we now? Life (Basel). 2022;12(4):517.
Silaghi-Dumitrescu R, Patrascu I, Lehene M, Bercea I. Comorbidities of COVID-19 Patients. Medicina (Kaunas). 2023;59(8):1393.
Belancic A, Kalauz M, Tiljak H, Likic R. Pathophysiological mechanisms behind possible cataract progression in patients after COVID-19. Psychiatr Danub. 2021;33(Suppl 13):424-5.
Singh AK, Misra A. Impact of COVID-19 and comorbidities on health and economics: Focus on developing countries and India. Diabetes Metab Syndr. 2020;14(6):1625-30.
Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547.
Sharma P, Behl T, Sharma N, Singh S, Grewal AS, Albarrati A, et al. COVID-19 and diabetes: Association intensify risk factors for morbidity and mortality. Biomed Pharmacother. 2022;151:113089.
Joshi SR. COVID-19 Care in India: Evolving paradigms from public health to critical care. J Assoc Physicians India. 2020;68(10):56-58.
Laxminarayan R, B CM, G VT, Arjun Kumar KV, Wahl B, Lewnard JA. SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study. Lancet Infect Dis. 2021;21(12):1665-76.
Kansara N, Nandapurkar AB, Maniyar R, Yadav AK. Prediction of mortality by age and multi-morbidities among confirmed COVID-19 patients: Secondary analysis of surveillance data in Pune, Maharashtra, India. Ind J Publ Health. 2021;65(1):64-6.
Downloads
Published
How to Cite
Issue
Section
